Synonyms: CE-224,535 | CE-224535 | compound 3 [PMID: 21782426] | compound 33 [PMID: 21565499]
Compound class:
Synthetic organic
Comment: PF-04905428 is an investigational purinergic receptor 2 (P2X7) antagonist [2,4], with potential antiinflammatory action in various conditions such as arthritis, allergies, asthma, COPD, autoimmune diseases and other disorders.. PF-04905428 is one of the compounds claimed in patent US6974812 [1].
|
|
Bioactivity Comments |
PF-04905428 was tested for its ability to inhibit lL-1β release from ATP-stimulated monocytes. This assay provides an IC50 of 1.3nM [4]. We have tagged P2X7 receptor as the primary molecular target based on details in [2] and [1], despite neither of these publications containing a bona fide affinity value for PF-04905428 binding. The selectivity of PF-04905428 for the human P2X7 receptor precludes its evaluation in rodent disease models. |
Selectivity at ion channels | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|